Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Net Cash Flow: 2016-2025

Historic Net Cash Flow for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $29.1 million.

  • Akebia Therapeutics' Net Cash Flow rose 632.35% to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $132.4 million, marking a year-over-year increase of 1160.93%. This contributed to the annual value of $9.0 million for FY2024, which is 118.46% up from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Net Cash Flow is $29.1 million, which was up 21.73% from $23.9 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Net Cash Flow registered a high of $61.5 million during Q1 2025, and its lowest value of -$57.4 million during Q4 2021.
  • Over the past 3 years, Akebia Therapeutics' median Net Cash Flow value was -$2.5 million (recorded in 2024), while the average stood at $6.8 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Net Cash Flow plummeted by 919.93% in 2023, and later soared by 6,527.27% in 2025.
  • Akebia Therapeutics' Net Cash Flow (Quarterly) stood at -$57.4 million in 2021, then climbed by 4.75% to -$54.7 million in 2022, then spiked by 93.42% to -$3.6 million in 2023, then surged by 596.30% to $17.9 million in 2024, then spiked by 632.35% to $29.1 million in 2025.
  • Its last three reported values are $29.1 million in Q3 2025, $23.9 million for Q2 2025, and $61.5 million during Q1 2025.